Company

Viatris Inc.

Headquarters: Canonsburg, PA, United States

Founded: November 16, 2020

Employees: 37,000

CEO: Mr. Michael Goettler

show_chart NASDAQ: VTRS -0.08%

Market Cap

$14.37 Billion

USD as of Jan. 1, 2023

history Market Cap History

Viatris Inc. market capitalization over time

Evolution of Viatris Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Viatris Inc.

Detailed Description

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Stocks & Indices

Viatris Inc. has the following listings and related stock indices.


Stock: NASDAQ: VTRS

Stock: BMV: VTRS

Stock: FSX: VIA

Stock: MTA: VTRS

Stock: Munich: VIA

Stock: XETR: VIA

Product & Services

Branded and generic pharmaceuticals and active pharmaceutical ingredients

Key People

Robert J. Coury (Executive Chairman) Michael Goettler (CEO) Sanjeev Narula (CFO) W. Don Cornwell (Director) James M. Kilts (Director) Ian Read (Director)

Financials

Revenue: US$11.946 billion (2020)

Net income: US$0.670 billion (2020)


Total assets: US$61.553 billion (2020)

Total equity: US$22.951 billion (2020)

Details

Headquarters:

1000 Mylan Boulevard

Canonsburg, PA 15317

United States

Phone: 724 514 1968